You're reading: Time: Moderna’s COVID-19 vaccine moves to Phase 2 testing

Time: Moderna’s COVID-19 vaccine moves to Phase 2 testing

By Time.

Published May 13, 2020 at 2:08 am

A picture taken on Jan. 12, 2020 shows a World Health Organization (WHO) sign at its headquarters prior to a combined news conference following a two-day international conference on COVID-19 coronavirus vaccine research and a meeting to decide whether Ebola in DR Congo still constitutes health emergency of international concern in Geneva.

Photo by AFP

On May 12, Moderna Therapeutics, based in Cambridge, Mass., received fast-track approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine candidate, mRNA-1273. Days earlier, the FDA gave the company the green light to proceed to Phase 2 testing of the vaccine, which is expected to begin shortly.